Hepatocellular carcinoma is the most common form of primary liver cancer, and globally it is the sixth most common cancer. In this study, we use liposomes that can co-encapsulate the therapeutic agent (oxaliplatin or gemcitabine) in addition to iron oxide nanoparticles to enable MRI-monitored local delivery of the therapeutic agent to limit proangiogenic responses in non-resectable liver tumors following transcatheter embolotherapies. The results showed increased R2* values in the tumor regions at one week post-infusion, compared to the surrounding liver parenchyma and to same regions immediately after infusion, which allows for confirmation of procedural success and proper catheter-selective tumor targeting.
This abstract and the presentation materials are available to members only; a login is required.